sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot study
Not Applicable
- Conditions
- advanced and recurrent non-small cell lung cancer
- Registration Number
- JPRN-UMIN000031095
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with serious liver dysfunction or renal dysfunction 2)Pregnant or lactating females 3)Patients with clinically significant psychiatric disease that would interfere with participation in this study 4)Patients with history of previous immune checkpoint inhibitor treatment 5)Patients with history of autoimmune diseases 6)Patients with serious interstitial lung disease or infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate correlation between response rates of immune checkpoint inhibitors by PERCIST, by thallium scintigraphy and by RECIST before and 8 weeks after treatment.
- Secondary Outcome Measures
Name Time Method To evaluate correlation between response rates of immune checkpoint inhibitors by PERCIST, by thallium scintigraphy and progression free survival and overall survival.